2022
DOI: 10.7759/cureus.24237
|View full text |Cite
|
Sign up to set email alerts
|

A Case of Thrombotic Microangiopathy Secondary to Hypertensive Emergency

Abstract: Hypertension causing thrombotic microangiopathy (TMA) is one of the several etiologies of TMA, which causes endothelial damage and thrombosis of microvasculature, leading to hemolytic anemia, thrombocytopenia, and ischemic organ damage. Renal microvasculature involvement leading to renal dysfunction is most frequently seen in TMA but the degree of dysfunction varies with etiology. If left untreated, TMA carries a risk of high mortality, so it is extremely important for early identification of the cause of TMA.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 12 publications
0
2
0
Order By: Relevance
“…[74,75] Several patients have been reported to be in remission with blood pressure control alone without PE. [76–78] In this case, malignant hypertension-induced TMA was considered; however, severe thrombocytopenia was observed and atypical. Several previous reports on COVID-19-related TMA have described patients with a history of hypertension.…”
Section: Discussionmentioning
confidence: 99%
“…[74,75] Several patients have been reported to be in remission with blood pressure control alone without PE. [76–78] In this case, malignant hypertension-induced TMA was considered; however, severe thrombocytopenia was observed and atypical. Several previous reports on COVID-19-related TMA have described patients with a history of hypertension.…”
Section: Discussionmentioning
confidence: 99%
“…Hypertension-associated microangiopathy and atypical hemolytic uremic syndrome share a similar ultrastructural appearance with light microscopy. In our case, severe uncontrollable hypertension appeared to trigger complement activation and endothelial damage leading to TMA [ 6 , 7 ]. Moreover excellent response to eculizumab further confirmed this.…”
mentioning
confidence: 99%